Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia
Moreno C, Stilgenbauer S, Montillo M, et al.
Key Points:
- Authors present data to ascertain the use of prognostic and predictive markers in CLL patients (ERIC database)
- Most frequently evaluated parameters (at diagnosis) by >80% of the participants: age, disease stage, ECOG, B-symptoms, WBC count, LDT, tumor bulk, DAT, LDH and B2M
- Parameters evaluated (at diagnosis) by >70% of the participants: FISH for 13q-, 11q-, 17p-, and +12
- More frequently evaluated biomarkers: IGHV mutational status (54%); TP53 mutations (25%)
- 60% participants re-assess prognostic parameters over the course of the disease
- Features evaluated prior to initiating treatment: standard clinical parameters, ECOG (96%), DAT (77%), CIRS (66%) and bone marrow (45%)
- 17p- and 11q- studied by 79% and 68% of investigators, respectively.
Implications:
- Study provides data useful as basis for refining recommendations about evaluation and prognostication of patients with CLL based on what is actually done in daily practice.
View the original abstract on the ASH website.
